---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-011517"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:13:25.016691+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INmune Bio details CORDStrom regulatory path for RDEB; Phase 2 data shows itch reduction

## Summary
- CORDStrom Phase 2 in 30 RDEB patients met endpoints on itch and skin scores; well tolerated with no related AEs.
- FDA granted Rare Pediatric Disease and Orphan Drug Designations; Type C meeting completed; pre-BLA meeting planned.
- Open-label trial starts mid-2025 in UK; INmune to file IND for US inclusion; BLA submission targeted by YE 2025.
- Potential US approval/launch in 2026; also seeking MAAs in UK and EU; >$1B peak sales opportunity for ~4,500 patients.

## SEC filing metadata
- accession: 0001213900-25-011517
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025011517/0001213900-25-011517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025011517/ea0230471-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-011517
- JSON: https://secwatch.observer/filing/0001213900-25-011517.json
- Plain text: https://secwatch.observer/filing/0001213900-25-011517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.